Multidisciplinary Pain Center, Antwerp University Hospital (UZA), Edegem, Belgium.
ASTARC, University of Antwerp (UA), Antwerp, Belgium.
Pain Res Manag. 2023 Apr 14;2023:7708982. doi: 10.1155/2023/7708982. eCollection 2023.
A qualitative evaluation study of the prematurely terminated PrEgabalin Lidocaine Capsaicin Neuropathic Pain (PELICAN) study was performed. The PELICAN study aimed to examine pain management for localized neuropathic pain (LNP), as epidemiological figures have shown a high percentage of LNP patients in Belgium. The study compared systemic and topical medications according to pain relief, adverse effects, and several measures of quality of life.
Achieving better study patient recruitment through qualitative research. To investigate and determine the causes of the observed recruitment problems in the PELICAN study, pain centers involved in the study as well as nonrecruiting pain centers were included. Furthermore, it aimed to highlight the positive and negative lessons learned from the conducted study and the number of obstacles the team had to overcome.
A qualitative study, using a mixed methods approach, was performed. Multiple pain centers in Belgium completed an online survey, after which a structured interview was conducted to elaborate the responses in more detail. The broad topics of these meetings were feedback about the study, reviewing survey answers, and actions undertaken to enhance recruitment.
Different factors contributed to the low recruitment rate in the PELICAN study, such as limited and late referral from the general practitioners to the Belgian pain centers, insufficient internal referrals from nonpain specialists, lack of specific expertise on LNP in some centers, scarcity of staff, limited reimbursement to administer complex analgesic schemes, overestimation of the patient population, and the reluctance of patients to participate in pain research. Additionally, shortcomings in the implemented study design and the need for more logistical investments were identified.
The findings of the qualitative study demonstrate the need for further, more varied LNP research in Belgium, not limited to pharmacological studies. It also sheds important light on the recruitment obstacles that may be faced during these studies. Future studies could support this research by offering better proposals for feasibility and recruitment, for instance, by designing and conducting a compelling pilot study or applying social media during the recruitment phase. . This trial is registered with NCT03348735. EUDRACT number 2018-003617-17.
对提前终止的普瑞巴林-利多卡因-辣椒素治疗神经病理性疼痛(PELICAN)研究进行了定性评估。PELICAN 研究旨在检查局部神经病理性疼痛(LNP)的疼痛管理,因为流行病学数据显示比利时有很高比例的 LNP 患者。该研究根据疼痛缓解、不良反应和生活质量的几个衡量标准比较了全身和局部药物治疗。
通过定性研究实现更好的研究患者招募。为了调查和确定 PELICAN 研究中观察到的招募问题的原因,研究涉及的疼痛中心和未招募的疼痛中心都被包括在内。此外,它旨在突出从已进行的研究中吸取的积极和消极教训,以及团队必须克服的障碍数量。
采用混合方法的定性研究。比利时的多个疼痛中心完成了在线调查,然后进行了结构化访谈,以更详细地阐述答复。这些会议的主题包括对研究的反馈、审查调查答复以及为加强招募而采取的行动。
导致 PELICAN 研究招募率低的因素有很多,例如全科医生向比利时疼痛中心的转诊有限且延迟、非疼痛专家的内部转诊不足、一些中心对 LNP 缺乏特定专业知识、人员短缺、管理复杂镇痛方案的报销有限、对患者人群的高估以及患者对疼痛研究的参与意愿不足。此外,还确定了实施研究设计的不足和需要更多后勤投资的问题。
定性研究的结果表明,比利时需要进一步开展更多样化的 LNP 研究,不仅限于药理学研究。它还重要地揭示了在这些研究中可能面临的招募障碍。未来的研究可以通过提供更好的可行性和招募建议来支持这项研究,例如,设计和进行引人入胜的试点研究或在招募阶段应用社交媒体。这项试验在 NCT03348735 注册。Eudract 编号:2018-003617-17。